ASND
Ascendis Pharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Buy"
High Gross Profit Margin
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ASND
Ascendis Pharma A/S
A leading, fully integrated biopharma company
Biological Technology
09/21/2006
01/28/2015
NASDAQ Stock Exchange
1,017
12-31
Depository Receipts (Ordinary Shares)
Tuborg Boulevard 12, DK-2900 Hellerup, Denmark
--
Ascendis Pharma A/s was established on September 21, 2006. The company is a clinical-stage biopharmaceutical company that uses its TransCon technology to develop a pipeline of optimal long-acting drug therapies to address significant unmet medical needs in a large market. The company is developing its lead product candidate, TransCon human growth hormone or growth hormone TransCon, once a week for the treatment of growth hormone deficiency and other diseases.
Earnings Call
Q3/2025
Estimate EPS-0.185472
Actual EPS-1.17
Estimate Revenue244.44M
Actual Revenue250.69M
Ascendis Pharma's Q3 2025: Contradictions Emerge on Conversion Rates, U.S. Enrollment, Reimbursement, and Seasonality Impact
Nov 13,2025 09:00
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ASND has released its 2025 Q3 earnings. EPS was reported at -1.17, versus the expected -0.185472, missing expectations. The chart below visualizes how ASND has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ASND has released its 2025 Q3 earnings report, with revenue of 250.70M, reflecting a YoY change of 288.95%, and net profit of -71.57M, showing a YoY change of 35.26%. The Sankey diagram below clearly presents ASND's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
